Allogeneic fibroblasts ameliorate intervertebral disc degeneration by reducing osteophytes in rabbits.

IF 3.1 3区医学 Q1 MEDICINE, GENERAL & INTERNAL

Frontiers in Medicine Pub Date : 2024-11-01 eCollection Date: 2024-01-01 DOI:10.3389/fmed.2024.1488727

Chen Chen, Yizhuo Huang, Lei Shi, Li Zhou, Shenao Zhou, Hongjin Wan, Xiao Yang, Jie Zhao

{"title":"Allogeneic fibroblasts ameliorate intervertebral disc degeneration by reducing osteophytes in rabbits.","authors":"Chen Chen, Yizhuo Huang, Lei Shi, Li Zhou, Shenao Zhou, Hongjin Wan, Xiao Yang, Jie Zhao","doi":"10.3389/fmed.2024.1488727","DOIUrl":null,"url":null,"abstract":"Introduction: Low back pain (LBP) was commonly induced by intervertebral disc degeneration (IVDD), which is accompanied by the loss of disc height and osteophyte generation. Cell-based therapy is a promising treatment for preventing the degeneration of interverbral disc. In our study, allogeneic fibroblasts are shown to ameliorate intervertebral disc degeneration by reducing osteophytes in rabbits.Methods: We established a rabbits-derived fibroblast (Rab-Fib) which could be expanded in vitro and constructed puncture-induced intervertebral disc degeneration rabbit model. Histologic and imaging examinations and analyses were performed after 2 weeks, 3 months, and 12 months.Results: Our data indicate that stable and reliably-extracted allogeneic fibroblasts can effectively ameliorate intervertebral disc degeneration by reducing osteophytes.Conclusion: Our study provides a basis for advancing the further translation of fibroblasts in intervertebral disc therapy.","PeriodicalId":12488,"journal":{"name":"Frontiers in Medicine","volume":"11 ","pages":"1488727"},"PeriodicalIF":3.1000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11567068/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3389/fmed.2024.1488727","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Low back pain (LBP) was commonly induced by intervertebral disc degeneration (IVDD), which is accompanied by the loss of disc height and osteophyte generation. Cell-based therapy is a promising treatment for preventing the degeneration of interverbral disc. In our study, allogeneic fibroblasts are shown to ameliorate intervertebral disc degeneration by reducing osteophytes in rabbits.

Methods: We established a rabbits-derived fibroblast (Rab-Fib) which could be expanded in vitro and constructed puncture-induced intervertebral disc degeneration rabbit model. Histologic and imaging examinations and analyses were performed after 2 weeks, 3 months, and 12 months.

Results: Our data indicate that stable and reliably-extracted allogeneic fibroblasts can effectively ameliorate intervertebral disc degeneration by reducing osteophytes.

Conclusion: Our study provides a basis for advancing the further translation of fibroblasts in intervertebral disc therapy.

查看原文本刊更多论文

异体成纤维细胞通过减少兔子骨质增生改善椎间盘退变

简介腰背痛（LBP）通常由椎间盘退变（IVDD）引起，伴随着椎间盘高度下降和骨质增生。细胞疗法是预防椎间盘退变的一种很有前景的治疗方法。在我们的研究中，异体成纤维细胞通过减少兔子的骨质增生改善了椎间盘退变：方法：我们建立了一种可在体外扩增的兔源性成纤维细胞（Rab-Fib），并构建了穿刺诱导的椎间盘退变兔模型。分别在 2 周、3 个月和 12 个月后进行组织学和影像学检查和分析：结果：我们的数据表明，稳定、可靠提取的异体成纤维细胞可通过减少骨质增生有效改善椎间盘退变：我们的研究为推动成纤维细胞在椎间盘治疗中的进一步应用奠定了基础。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Frontiers in Medicine Medicine-General Medicine

CiteScore

5.10

自引率

5.10%

发文量

3710

审稿时长

12 weeks

期刊介绍： Frontiers in Medicine publishes rigorously peer-reviewed research linking basic research to clinical practice and patient care, as well as translating scientific advances into new therapies and diagnostic tools. Led by an outstanding Editorial Board of international experts, this multidisciplinary open-access journal is at the forefront of disseminating and communicating scientific knowledge and impactful discoveries to researchers, academics, clinicians and the public worldwide. In addition to papers that provide a link between basic research and clinical practice, a particular emphasis is given to studies that are directly relevant to patient care. In this spirit, the journal publishes the latest research results and medical knowledge that facilitate the translation of scientific advances into new therapies or diagnostic tools. The full listing of the Specialty Sections represented by Frontiers in Medicine is as listed below. As well as the established medical disciplines, Frontiers in Medicine is launching new sections that together will facilitate - the use of patient-reported outcomes under real world conditions - the exploitation of big data and the use of novel information and communication tools in the assessment of new medicines - the scientific bases for guidelines and decisions from regulatory authorities - access to medicinal products and medical devices worldwide - addressing the grand health challenges around the world